Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Poor adherence to pharmacotherapy during maintenance-phase treatment of bipolar disorder is a common occurrence, exposing patients to a high risk of illness relapses, rehospitalization and other negative outcomes. In view of this, there has been a reawakening of interest in the potential of long-acting injectable antipsychotic medications to improve treatment outcome during bipolar maintenance therapy. Indeed, long-acting injectable medications have practical advantages of assuring delivery of medication at a prescribed dose, and perhaps also making it easier to monitor adherence, at least to the long-acting drug. However, there are important limitations to the long-term use of depot typical neuroleptics in patients with bipolar disorder, including risk of extrapyramidal side effects and tardive dyskinesia, which may exceed that of patients with schizophrenia, and the potential for treatment-emergent exacerbation of depressive symptoms. Long-acting injectable risperidone (RLAI) has recently been approved for maintenance treatment in patients with bipolar I disorder. Evidence supporting the use of RLAI for this indication consists of several nonrandomized, open-label studies; one randomized, open-label trial; and two adequately powered randomized, double-blind trials. In general, these studies have shown RLAI to be effective for the prevention of relapse or hospitalization during bipolar maintenance treatment. In the double-blind studies, RLAI was associated with reduced relapse rates, increased time to relapse and greater control of clinical symptoms during maintenance treatment following initial stabilization, compared with oral medication treatment or placebo injection. RLAI appeared to be more effective for preventing manic/mixed episodes than depressive episodes. RLAI showed good tolerability across studies; however, dose-related extrapyramidal effects, sedation, weight gain and prolactin elevation may occur during long-term treatment. Responder-enriched designs and exclusion of important clinical subgroups in the double-blind trials may limit translation of these results to routine care settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons
Woolcott, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.357 · Cited by 1,326
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869
Relapse and impairment in bipolar disorder
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1635 · Cited by 762
Screening for Bipolar Disorder in the Community
Hirschfeld, R. M. A., Calabrese, J. R., Weissman, M. M., Reed, M., Davies, M. A., Frye, M. A., Keck, P. E., Lewis, L., McElroy, S. L., McNulty, J. P., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0111 · Cited by 674
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Grant, B. F., Stinson, F. S., Hasin, D. S., Dawson, D. A., Chou, S. P., Ruan, W. J., & Huang, B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1001 · Cited by 479
Nonadherence With Mood Stabilizers: Prevalence and Predictors
Scott, J., & Pope, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0502 · Cited by 315
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.6.805 · Cited by 281
Suicide risk in bipolar patients: the role of co‐morbid substance use disorders
Dalton, E. J., Cate‐Carter, T. D., Mundo, E., Parikh, S. V., & Kennedy, J. L. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00017.x · Cited by 275
Yatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248
Treatment adherence with antipsychotic medications in bipolar disorder
Sajatovic, M., Valenstein, M., Blow, F. C., Ganoczy, D., & Ignacio, R. V. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00314.x · Cited by 242
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200
Birkenaes, A. B., Opjordsmoen, S., Brunborg, C., Engh, J. A., Jonsdottir, H., Ringen, P. A., Simonsen, C., Vaskinn, A., Birkeland, K. I., Friis, S., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0614 · Cited by 185
Shores, M. M., Moceri, V. M., Sloan, K. L., Matsumoto, A. M., & Kivlahan, D. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0102 · Cited by 166
Flupenthixol decanoate in recurrent manic‐depressive illness: A COMPARISON WITH LITHIUM
Ahlfors, U. G., Baastrup, P. C., Dencker, S. J., Elgen, K., Lingjærde, O., Pedersen, V., Schou, M., & Aaskoven, O. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00778.x · Cited by 155
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
Enhancing medication adherence in patients with bipolar disorder
Berk, L., Hallam, K. T., Colom, F., Vieta, E., Hasty, M., Macneil, C., & Berk, M. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1081 · Cited by 149
Gefvert, O., Eriksson, B., Persson, P., Helldin, L., Björner, A., Mannaert, E., Remmerie, B., Eerdekens, M., & Nyberg, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004924 · Cited by 119
Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS-R)
Nierenberg, A. A., Akiskal, H. S., Angst, J., Hirschfeld, R. M., Merikangas, K. R., Petukhova, M., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.61 · Cited by 60
Rapid-cycling bipolar disorder: cross-national community study
Lee, S., Tsang, A., Kessler, R. C., Jin, R., Sampson, N., Andrade, L., Karam, E. G., Mora, M. E. M., Merikangas, K., Nakane, Y., et al. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067843 · Cited by 57
Thyssen, A., Rusch, S., Herben, V., Quiroz, J., & Mannaert, E. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009355156 · Cited by 26
Cited by
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Stewart, S. A., Domínguez-Robles, J., Donnelly, R. F., & Larrañeta, E. (2018) · Polymers · doi:10.3390/polym10121379 · Cited by 390
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
A Comprehensive Map of FDA-Approved Pharmaceutical Products
Zhong, H., Chan, G., Hu, Y., Hu, H., & Ouyang, D. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040263 · Cited by 288
Microneedle array systems for long-acting drug delivery
Vora, L. K., Moffatt, K., Tekko, I. A., Paredes, A. J., Volpe-Zanutto, F., Mishra, D., Peng, K., Raj Singh Thakur, R., & Donnelly, R. F. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.12.006 · Cited by 270
Metadata
- Authors
- Bobo, W. V., & Shelton, R. C.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2010-11
- Volume
- 10
- Issue
- 11
- Pages
- 1637-1658
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2131290715
- Cited by
- 50
- References
- 25
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.